| Literature DB >> 23139791 |
Hayley R Inglis1, Judith M Greer, Pamela A McCombe.
Abstract
BACKGROUND: Experimental autoimmune encephalomyelitis (EAE), the best available model of multiple sclerosis, can be induced in different animal strains using immunization with central nervous system antigens. EAE is associated with inflammation and demyelination of the nervous system. Micro-array can be used to investigate gene expression and biological pathways that are altered during disease. There are few studies of the changes in gene expression in EAE, and these have mostly been done in a chronic mouse EAE model. EAE induced in the Lewis with myelin basic protein (MBP-EAE) is well characterised, making it an ideal candidate for the analysis of gene expression in this disease model. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2012 PMID: 23139791 PMCID: PMC3491034 DOI: 10.1371/journal.pone.0048555
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Clinical course of EAE. A.
The figure shows the results of a clinical course experiment (n = 10) in which female Lewis rats (10–12 wks old) were injected with 50 µg Guinea Pig MBP emulsified in incomplete Freund’s Adjuvant containing 4 mg/ml heat inactivated M.Butyricium. The peak of disease generally occurs between 12 and 14 days post injection and resolves, usually within 7–10 days later. Mild relapses occur in a few animals between 28 and 40 dpi. B. Spinal cords used to prepare RNA for microarray analysis were collected on day 13 when the disease course was either at its peak or in the phase of very early resolution. Clinical course scores were recorded using a 12 point scale [43].
Figure 2Volcano plot.
This shows the significance (y axis) versus the fold change (x axis) for genes in rats with EAE compared to healthy controls.
Genes most significantly up-regulated at the peak of Clinical disease in MBP induced EAE in the Lewis Rat.
| Entrez gene symbol | Entrez Gene Name | Fold change | p-value | QTL | Function | Previous association with EAE or Inflammation in the CNS | Ref |
|
| CD74 molecule, major histocompatibility complex, class II invariant chain | 139.3 | 3.35E–07 |
| Antigen processing and presentation |
|
|
|
| proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) | 8.2 | 8.80E–10 |
| Antigen processing and presentation |
|
|
|
| rat major histocompatibility complex, class I | 6.5 | 2.06E–05 | – | Antigen processing and presentation | – | – |
|
| rat major histocompatibility complex, class II, RTI-DM β chain | 9.2 | 2.37E–05 | – | Antigen processing and presentation | – | – |
|
| rat major histocompatibility complex, class II, RT1-B α chain | 32.7 | 1.33E–06 | – | Antigen processing and presentation |
|
|
|
| rat major histocompatibility complex, class II, RT1-D α chain | 116.7 | 4.04E–06 | – | Antigen processing and presentation |
|
|
|
| rat major histocompatibility complex, class II, RT1-Dβ 1 chain | 8.3 | 7.54E–05 | – | Antigen processing and presentation |
|
|
|
| transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) | 4.3 | 1.08E–06 |
| Antigen processing and presentation |
|
|
|
| TIMP metallopeptidase inhibitor 1 | 8.0 | 2.86E–05 | Antigen processing and presentation |
|
| |
|
| caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) | 6.3 | 4.48E–06 | – | Apoptosis and cell death |
|
|
|
| caspase 4, apoptosis-related cysteine peptidase | 7.1 | 2.52E–06 | – | Apoptosis and cell death | Oligodendrocyte cell death in MOG induced EAE in mice was mediated by a pathway that involves |
|
|
| caspase 8, apoptosis-related cysteine peptidase | 4.3 | 1.93E–05 | – | Apoptosis and cell death |
|
|
|
| guanine deaminase | 15.1 | 5.82E–06 | – | Apoptosis and cell death | – | – |
|
| interferon regulatory factor 1 | 8.6 | 5.89E–06 |
| Apoptosis and cell death |
|
|
|
| immunity-related GTPase family, M | 14.0 | 1.93E–05 |
| Apoptosis and cell death |
|
|
|
| lipocalin 2 | 75.2 | 5.72E–06 | – | Apoptosis and cell death |
|
|
|
| toll-like receptor 2 | 6.0 | 4.77E–05 | – | Apoptosis and cell death |
|
|
|
| Tlr4 | 4.9 | 8.16E–04 | – | Apoptosis and cell death |
|
|
|
| transient receptor potential cation channel, subfamily M, member 2 | 4.6 | 8.25E–05 | – | Apoptosis and cell death | – | – |
|
| ubiquitin D | 4.3 | 7.31E–04 | – | Apoptosis and cell death | – | – |
|
| annexin A3 | 8.1 | 5.01E–06 | – | Cellular movement | – |
|
|
| chemokine (C-C motif) ligand 7 | 6.7 | 2.65E–04 |
| Cellular movement |
|
|
|
| chemokine (C-C motif) receptor 5 | 6.5 | 2.25E–05 | – | Cellular movement |
|
|
|
| chemokine (C-X3-C motif) receptor 1 | 5.6 | 1.19E–03 | – | Cellular movement |
|
|
|
| chemokine (C-X-C motif) ligand 9 | 113.50 | 2.51E–06 | – | Cellular movement |
|
|
|
| chemokine (C-X-C motif) ligand 16 | 20.1 | 5.28E–06 |
| Cellular movement |
|
|
|
| fibronectin 1 | 5.3 | 1.35E–03 | – | Cellular movement | – | – |
|
| apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 | 46.8 | 5.61E–05 |
| Cellular growth and proliferation |
|
|
|
| glycoprotein (transmembrane) nmb | 16.1 | 2.89E–05 | – | Cellular growth and proliferation | – | – |
|
| Granulin | 6.0 | 1.61E–05 | – | Cellular growth and proliferation |
|
|
|
| interleukin 2 receptor, alpha | 7.6 | 1.94E–04 | – | Cellular growth and proliferation | MOG Induced EAE susceptible DA rats had higher |
|
|
| interleukin 2 receptor, gamma | 34.7 | 3.46E–07 | – | Cellular growth and proliferation | Common cytokine receptor gamma-chain (gamma(c)) family cytokines have crucial roles in the development, proliferation, survival and differentiation of multiple cell lineages of both the innate and adaptive immune systems. |
|
|
| killer cell lectin-like receptor subfamily K, member 1 | 13.5 | 2.66E–05 | – | Cellular growth and proliferation | – | – |
|
| lysosomal protein transmembrane 5 | 9.2 | 5.08E–04 | – | Cellular growth and proliferation | – | – |
|
| signal transducer and activator of transcription 1, 91 kDa | 12.5 | 2.11E–05 | – | Cellular growth and proliferation | Expression of |
|
|
| interferon regulatory factor 8 | 4.8 | 1.37E–05 | – | Cellular development and differentiation | – | – |
|
| rho GDP dissociation inhibitor (GDI) beta | 8.4 | 1.18E–04 |
| Cell- cell signalling and interaction |
|
|
|
| egf-like module containing, mucin-like, hormone receptor-like 1 | 16.9 | 1.60E–06 | – | Cell- cell signalling and interaction |
| – |
|
| protein kinase C, delta | 4.1 | 2.49E–04 | – | Cell- cell signalling and interaction |
| – |
|
| platelet-activating factor receptor | 6.5 | 3.74E–05 | – | Cell- cell signalling and interaction |
| – |
|
| ras-related C3 botulinum toxin substrate 2 (rho family, small GTP binding protein Rac2) | 6.5 | 2.31E–06 | – | Cell- cell signalling and interaction |
| – |
|
| TYRO protein tyrosine kinase binding protein | 7.3 | 2.02E–04 | – | Cell- cell signalling and interaction |
|
|
|
| complement component 3 | 26.1 | 4.58E–05 | – | Complement activation |
|
|
|
| complement component 1, q subcomponent, A chain | 5.8 | 1.27E–04 | – | Complement activation | The complement system has previously been implicated in the development of EAE, |
|
|
| complement component 1, q subcomponent, B chain | 4.6 | 1.06E–03 | – | Complement activation | The complement system has previously been implicated in the development of EAE |
|
|
| complement component 1, q subcomponent, C chain | 10.6 | 8.76E–05 | – | Complement activation | The complement system has previously been implicated in the development of EAE |
|
|
| complement component 3a receptor 1 | 4.1 | 1.43E–03 |
| Complement activation |
|
|
|
| complement factor B | 4.7 | 2.89E–04 | – | Complement activation | – | |
|
| serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 | 20.5 | 7.24E–05 | – | Complement activation | – | – |
|
| sterol O-acyltransferase 1 | 4.8 | 1.72E–05 |
| Complement activation |
|
|
|
| Bruton agammaglobulinemia tyrosine kinase | 5.5 | 1.80E–05 | – | Inflammatory Response | – | – |
|
| CD4 molecule | 12.5 | 7.05E–07 |
| Inflammatory Response |
|
|
|
| CD14 molecule | 4.4 | 4.44E–03 |
| Inflammatory Response |
|
|
|
| CD86 molecule | 10.5 | 7.23E–06 | – | Inflammatory Response |
|
|
|
| chitinase 3-like 1 (cartilage glycoprotein-39) | 9.1 | 7.66E–04 |
| Inflammatory Response |
|
|
|
| Fc fragment of IgG, low affinity IIa, receptor (CD32) | 9.5 | 2.69E–04 |
| Inflammatory Response |
|
|
|
| Fc fragment of IgG, low affinity IIb, receptor (CD32) | 11.6 | 6.35E–06 |
| Inflammatory Response |
|
|
|
| coagulation factor X | 5.4 | 4.64E–04 | – | Inflammatory Response | – | – |
|
| interleukin 1, beta | 4.8 | 1.37E–03 | – | Inflammatory Response |
|
|
|
| interleukin 1 receptor antagonist | 7.5 | 7.42E–04 | – | Inflammatory Response |
|
|
|
| v-yes-1 Yamaguchi sarcoma viral related oncogene homolog | 9.4 | 6.06E–08 | – | Inflammatory Response | Severity of EAE is increased in |
|
|
| protein tyrosine phosphatase, receptor type, C | 17.0 | 2.78E–07 |
| Inflammatory Response |
|
|
|
| vav 1 guanine nucleotide exchange factor | 4.0 | 4.36E–05 | – | Inflammatory Response |
| – |
|
| phosphorylase, glycogen, liver | 8.0 | 4.28E–06 | – | Other metabolic processes | – | – |
|
| ceruloplasmin (ferroxidase) | 6.8 | 5.35E–05 | – | Other metabolic processes |
|
|
Genes most significantly down-regulated at the peak of Clinical disease in MBP induced EAE in the Lewis Rat.
| Gene Symbol | Entrez Gene name | Fold change | p-value | QTL | Function | Previous association with EAE or Inflammation in the CNS | Ref |
|
| isopentenyl-diphosphate delta isomerase 1 | −3.4 | 5.34E–04 | – | Cholesterol Biosynthesis | – | – |
|
| 3-hydroxy-3-methylglutaryl-CoA synthase 1 | −3.2 | 1.28E–04 | – | Cholesterol Biosynthesis | – | – |
|
| cytochrome P450, family 51, subfamily A, polypeptide 1 | −2.9 | 2.31E–03 | – | Cholesterol Biosynthesis | Cytochhrome P450 dependent enzyme activities in the brain were reduced in both LPS induced and EAE models of inflammation in astrocytes in LPS induced inflammation. |
|
|
| methylsterol monooxygenase 1 | −2.4 | 4.67E–04 | – | Cholesterol Biosynthesis | – | – |
|
| sterol-C5-desaturase | −2.2 | 1.07E–03 | – | Cholesterol Biosynthesis | – | – |
|
| squalene epoxidase | −2.1 | 2.58E–03 | – | Cholesterol Biosynthesis | – | – |
|
| neuropeptide Y | −2.1 | 3.00E–04 |
| Cellular growth and proliferation |
|
|
|
| pleiotrophin | −2.1 | 7.33E–04 | – | Cellular growth and proliferation |
|
|
|
| septin 3 | −2.1 | 5.28E–04 | – | Cellular growth and proliferation | – | – |
|
| gap junction protein, beta 1 | −2.0 | 1.08E–03 | – | Cell-cell signalling and Interaction |
|
|
|
| growth factor receptor-bound protein 14 | −2.1 | 5.55E–04 |
| Cell-cell signalling and Interaction |
|
|
|
| histamine N-methyltransferase | −2.8 | 6.78E–04 | – | Cell-cell signalling and Interaction | – | – |
|
| interleukin 1 receptor accessory protein-like 1 | −2.5 | 2.29E–04 | – | Cell-cell signalling and Interaction | – | – |
|
| neuroligin 1 | −2.0 | 9.21E–04 | – | Cell-cell signalling and Interaction | – | |
|
| protein phosphatase 1, regulatory (inhibitor) subunit 14C | −2.2 | 1.74E–03 |
| Cell-cell signalling and Interaction |
|
|
|
| thyrotropin-releasing hormone receptor | −2.5 | 1.82E–03 | – | Cell-cell signalling and Interaction | – | – |
|
| UDP glycosyltransferase 8 | −2.2 | 3.64E–03 | – | Myelination | – | – |
|
| -galanin prepropeptide | −2.2 | 1.20E–04 |
| Inflammatory Response |
|
|
|
|
| −2.8 | 1.66E–03 | – | Post translational protein modification | – | – |
Figure 3RT- PCR validation of 5 genes expressed differentially in the spinal cords of Lewis rats with MBP induced EAE.
Tissue samples were snap frozen in liquid nitrogen and stored at −80°C prior to total RNA preparation using the QIAGEN RNeasy Lipid tissue kit. RNA quality analysis was carried out on the BioRadExperion automated electrophoresis system. All preparations used in both assays had RNA quality indicator (RQI) values of >9.5. For RT-PCR, total RNA was reverse transcribed and amplified as described in the methods. Analysis of selected genes up or down regulated at the peak of disease in EAE. Bars represent the average fold change between expression in the spinal cord level at peak of disease compared to normal healthy animals (+/− SEMs, Microarray n = 4, RT-PCR n = 8). Dark columns represent fold change derived from the microarray data. Similar amplification patterns were obtained from RT-PCR amplification of the same total RNA samples and a second set of 4 animals samples at an identical time point.
Cellular functions significantly up-regulated in MBP induced EAE in the Lewis rat.
| Function | Prediction | No of genes in direction of prediction | Z score | Overlap p-value | Genes for which expression direction predicts an increase in function | Genes for which expression direction predicts a decrease in function | Genes which affect the function |
| Activation of central nervous system cells | Increased |
| 2.268 | 2.83E–03 |
|
|
|
| Activation of astrocytes | Increased |
|
|
|
|
| |
| Apoptosis of leukocytes | Increased |
|
|
|
|
|
|
| Apoptosis of microglia | Increased |
|
|
|
|
| |
| Cell death of dopaminergic neurons | Increased |
|
|
|
|
|
|
| Formation of amyloid fibrils | Increased |
|
|
|
|
| |
| Proliferation of oligodendrocyte precursor cells | Increased |
|
|
|
|
Gene abbreviations are given in Gene names in Bold indicate increased expression in EAE, normal italic font indicates decreased expression.
Cellular Functions significantly down-regulated in MBP induced EAE in the Lewis rat.
| Function | Prediction | No of genes in direction of prediction | Z score | Overlap p value | Genes for which expression direction predicts a decrease in function | Genes for which expression direction predicts an increase in function | Genes which affect the function |
| Long term-potentiation | Decreased |
| − |
|
|
|
|
| Neurotransmission | Decreased |
| − |
|
|
|
|
| Synaptic transmission | Decreased |
| − |
|
|
|
|
| Quantity of vesicles | Decreased |
| − |
|
|
| |
| Quantity of dendritic spines | Decreased |
|
|
|
|
|
|
| Size of axons | Decreased |
| − |
|
| ||
| Delay in the death of neurons | Decreased |
| − |
|
|
Gene abbreviations are given in Gene names in Bold indicate increased expression in EAE, normal italic font indicates decreased expression.
Figure 4Summary of Canonical pathways that are regulated in MBP-EAE.
The most regulated canonical pathways are listed. The percentage of genes of each specific pathway that are up-regulated are shown in red and the percentage of genes that are down-regulated are shown in green. The genes involved in each pathway are shown in individual supplementary figures.
Upstream Regulators.
| Gene ID | Gene name | Molecular Type | Predicted Activation State | Fold Change | Activation z-score | p-value of overlap | Gene regulation consistent with activation (Number of genes regulated of all potential gene targets) | Genes regulation consistent with inhibition (Number of genes regulated of all potential gene targets) |
|
| Sirtuin2 | Transcription regulator | Inhibited | – | −3.317 | 3.85E–09 |
| |
|
| interleukin 1, beta | cytokine | Activated | 4.8 | 2.422 | 6.34E–06 |
|
|
|
| microtubule-associated protein tau | other | Activated | 2.0 | 9.66E–05 |
| ||
|
| CREB binding protein | Transcription regulator | Inhibited | – | −2.828 | 1.14E–04 |
| |
|
| signal transducer and activator of transcription 1 | Transcription regulator | Activated | 12.5 | 2.197 | 2.27E–04 |
|
|
|
| nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Transcription regulator | Inhibited | 3.8 | −2.125 | 4.04E–04 |
|
|
|
| tumor necrosis factor | cytokine | Activated | – | 3.575 | 7.32E–04 |
| |
|
| transforming growth factor, beta receptor II (70/80 kDa) | kinase | Activated | 3.1 | 2.137 | 1.61E–03 |
|
|
|
| nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | Ligand dependent nuclear receptor | Activated | – | 2.626 | 3.36E–03 |
| |
|
| tumor necrosis factor receptor superfamily, member 1A | Trans-membrane receptor | Activated | 1.8 | 2.000 | 3.78E–03 |
| |
|
| poly (ADP-ribose) polymerase 1 | enzyme | Activated | 1.6 | 2.429 | 9.30E–03 |
| |
|
| solute carrier family 30 (zinc transporter), member 3 | transporter | Inhibited | −1.3 | −2.000 | 1.98E–02 |
| |
|
| presenilin 2 | peptidase | Inhibited | – | −2.747 | 3.51E–02 |
|
|
Gene abbreviations are given in Gene names in indicate increased expression in EAE, normal italic font indicates decreased expression.